BrainsWay Says FDA Has Granted Expanded Indication For Deep Transcranial Magnetic Stimulation System
Portfolio Pulse from Benzinga Newsdesk
BrainsWay has received FDA clearance to expand the indication for its Deep Transcranial Magnetic Stimulation (TMS) system to treat patients with major depressive disorder (MDD) aged 22 to 86, up from the previous upper age limit of 68. This is the company's 10th FDA clearance and makes it the first TMS system approved for patients over 68 with MDD, including those with comorbid anxiety symptoms.
June 03, 2024 | 11:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BrainsWay has received FDA clearance to expand the indication for its Deep TMS system to treat MDD patients aged 22 to 86. This is the company's 10th FDA clearance and makes it the first TMS system approved for patients over 68 with MDD and comorbid anxiety symptoms.
The FDA clearance significantly expands the potential market for BrainsWay's Deep TMS system by including older patients with MDD and comorbid anxiety symptoms. This regulatory approval is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100